Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Status:
Terminated
Trial end date:
2018-05-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended
Phase 2 dose (RP2D) of weekly dosing of CRLX101 (both as monotherapy; (Schedule 1) and in
combination with bevacizumab every 2 weeks (Schedule 2) and weekly with a 3 week on / 1 week
off schedule in combination with mFOLFOX6 (Schedule 3) to affirm the dose for future clinical
studies.